ZURICH, May 4 (Reuters) - Actelion will appeal the final jury verdict in a licensing agreement dispute with Japanese group Asahi Kasei <3407.T>, the Swiss biotech group said on Wednesday, helping to ...

NJBIZ, New Jersey’s leading business journal, provides 24/7 business news coverage and events honoring top business professionals.

ALLSCHWIL, Switzerland (Reuters) - Swiss biotech Idorsia, spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson, will seek fresh funding in 2019 to support ...

An industrywide probe of pharma's charitable contributions has spawned multimillion-dollar kickback settlements, and Actelion is the latest to make a deal with the feds. The Johnson & Johnson unit ...

BOSTON-- The U.S. Attorney's Office announced today that pharmaceutical company Actelion Pharmaceuticals US, Inc. (Actelion), a seller of pulmonary arterial hypertension (PAH) drugs, has agreed to pay ...

U.S. healthcare giant Johnson & Johnson (JNJ.N) will buy Swiss biotech company Actelion (ATLN.S) in a $30 billion all-cash deal that includes spinning off Actelion's research and development pipeline, ...

Broadening its footprint in its key market of pulmonary arterial hypertension (PAH), while reducing its dependence on its Tracleer (bosentan) franchise, Actelion Ltd. entered a definitive agreement to ...

A pharmaceutical company has agreed to pay $360 million to resolve allegations that it used a charitable foundation to pay kickbacks to Medicare patients. The U.S. attorney's office in Boston ...

The chief executive officers of Actelion Ltd. and Amgen Inc. met last week to discuss Amgen’s interest in the Swiss biotechnology company, according to three people with knowledge of the situation.

ZURICH – Europe's largest biotech company Actelion said on Tuesday its chief financial officer Andrew Oakley would be leaving the company next week to focus on other opportunities. Oakley, who has ...